Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing (Q36371450)

13 August 2017

Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing (English)

1 reference

13 August 2017

1 reference

J van Rosmalen

1

1 reference

13 August 2017

I M C M de Kok

series ordinal

2

1 reference

13 August 2017

M van Ballegooijen

series ordinal

3

1 reference

13 August 2017

18 January 2012

1 reference

BJOG: an International Journal of Obstetrics and Gynaecology

13 August 2017

1 reference

13 August 2017

119

1 reference

13 August 2017

6

1 reference

13 August 2017

699-709

1 reference

Age-specific patterns of unsatisfactory results for conventional Pap smears and liquid-based cytology: data from two randomised clinical trials

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Health and economic implications of HPV vaccination in the United States

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Economic evaluation of human papillomavirus vaccination in the United Kingdom

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Human papillomavirus and Papanicolaou tests to screen for cervical cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489039

Human papillomavirus and cervical cancer

30 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

The health and economic effects of HPV DNA screening in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Cost-effectiveness of 21 alternative cervical cancer screening strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Benefits and costs of using HPV testing to screen for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Cervical cancer incidence in Denmark over six decades (1943-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

International correlation between human papillomavirus prevalence and cervical cancer incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2011.03228.X

Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries

21 January 2018

1 reference

12 December 2020

Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategies

1 reference

12 December 2020

A randomised comparison of SurePath liquid-based cytology and conventional smear cytology in a colposcopy clinic setting

1 reference

12 December 2020

Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types

1 reference

12 December 2020

Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands

1 reference

12 December 2020

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial

1 reference

12 December 2020

Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies

1 reference

12 December 2020

Cost-effectiveness of primary cytology and HPV DNA cervical screening

1 reference

12 December 2020

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

1 reference

12 December 2020

The MISCAN simulation program for the evaluation of screening for disease

1 reference

12 December 2020

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial

1 reference

12 December 2020

Economic evaluation of human papillomavirus screening in Germany

1 reference

12 December 2020

HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness

1 reference

12 December 2020

10.1111/J.1471-0528.2011.03228.X

Identifiers

DOI

1 reference

release_n5f4uyhoyvaldicbga2k2fi474

13 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n5f4uyhoyvaldicbga2k2fi474

24 November 2022

mapped directly with Wikidata item

1 reference

13 August 2017

1 reference